

RESEARCH ARTICLE

Open Access

Clinical characteristics in subjects with *NLRP3* V198M diagnosed at a single UK center and a review of the literature

Dorota M Rowczenio¹, Hadija Trojer¹, Tonia Russell¹, Anna Baginska¹, Thirusha Lane¹, Nicola M Stewart¹, Julian D Gillmore¹, Philip N Hawkins¹, Patricia Woo², Bozena Mikoluc³ and Helen J Lachmann^{1*}

Abstract

Introduction: Mutations in the *NLRP3* gene are associated with the dominantly inherited cryopyrin-associated periodic syndrome (CAPS). The significance of the V198M variant is unclear; it has been reported in association with various CAPS phenotypes and as a variant of uncertain consequence. The aim of this study was to characterize the clinical phenotypes and treatments in individuals with V198M assessed in a single UK center.

Methods: DNA samples from 830 subjects with fever syndromes or a family history of CAPS were screened for mutations in the *NLRP3* gene with polymerase chain reaction (PCR) and sequencing. A detailed medical history was available in all cases. Inflammatory disease activity was monitored monthly with measurements of serum amyloid A protein (SAA) and C-reactive protein (CRP) in symptomatic individuals.

Results: *NLRP3* V198M was identified in 19 subjects. It was found in association with CAPS in five cases, in one patient with Schnitzler syndrome, in three patients who also had a nucleotide alteration in another fever gene, and in three other patients with evidence of an autoinflammatory phenotype. Seven asymptomatic individuals were detected during screening of family members.

Conclusions: The *NLRP3* V198M variant shows variable expressivity and reduced penetrance. It may be associated with classical inherited or apparently sporadic CAPS and with atypical autoinflammatory disease of varying severity, intriguingly including Schnitzler syndrome. The factors that influence the pathogenic consequences of this variant remain unknown. However, the remarkable response to interleukin 1 (IL-1) blockade in all but one individual in our series confirms that their clinical features are indeed mediated by IL-1.

Introduction

Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disorder associated with overproduction of IL-1 β [1]. CAPS encompasses three individual phenotypically overlapping syndromes of differing severity, originally described as distinct entities but all subsequently linked to mutations in a single gene [2-5]. Familial cold autoinflammatory syndrome (FCAS, MIM 120100) was first described by Kile and Rusk in 1940 [6] and is the least severe, characterized by recurrent episodes of fever, urticaria-like rash, arthralgia, and

inflammatory eye manifestations induced by exposure to cool or damp environment [7,8]. Muckle-Wells syndrome (MWS, MIM 191900) resembles FCAS, but the disease is more severe and persistent and less obviously influenced by ambient temperature. Systemic inflammation in MWS starts in infancy or early childhood [9], and variable degrees of sensorineural deafness, often beginning in adolescence, occur in more than 60% of cases. Without effective treatment, between a quarter to a third eventually develop systemic AA amyloidosis [10]. Chronic infantile neurologic cutaneous articular syndrome (CINCA, MIM 607115), also known as neonatal-onset multisystem inflammatory disease (NOMID), has the most severe phenotype and presents in the neonatal period with involvement of many organs, including the

* Correspondence: h.lachmann@ucl.ac.uk

¹National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine Royal Free Campus, UCL Medical School, Rowland Hill Street, London NW3 2PF, UK

Full list of author information is available at the end of the article

skin, the skeleton, and the central nervous system. Dominant inheritance is evident in about 75% of patients with MWS and FCAS, whereas CINCA is usually sporadic; *de novo* mutations in *NLRP3* can be identified in about half of patients with CINCA, but the presumed genetic etiology in the remainder is yet to be characterized [5,11]. Symptomatic CAPS is accompanied by a striking acute-phase response, with serum concentrations of C-reactive protein (CRP) and serum amyloid A protein (SAA) frequently elevated by 100- to 1,000-fold, underlying the high risk of AA amyloidosis [10,12].

To date, 138 sequence variants of *NLRP3* have been identified, of which 110 have been associated with CAPS, and 28 are either nonpathogenic or of undetermined significance [13], the commonest of which is the Q703K variant (also described as Q705K in older literature) [14] that has been reported in 5% of healthy Caucasian alleles [11]. Pathogenic *NLRP3* variants result in substantial upregulation of caspase 1-mediated cleavage of pro IL-1 β and secretion of active IL-1 β , although the precise molecular mechanisms by which this occurs are yet to be elucidated fully. The *NLRP3* V198M variant (previously described as V200M) [10] is of particular interest because it has been reported in both individual patients and families with apparently classical CAPS [4,10,15]; in association with other autoinflammatory syndromes [16,17]; in patients with apparently acquired autoinflammatory disorders including the IgM paraprotein-related Schnitzler syndrome [18]; and in healthy Caucasian controls with an allele frequency of between 0.0038 [10] and 0.0074 [11].

We describe here the clinical phenotypes and treatments in individuals with V198M characterized in a single UK center and review the published literature regarding the clinical spectrum associated with this variant.

Materials and methods

Subjects and relatives

The *NLRP3* gene was analyzed in 830 subjects assessed at the single UK specialist center between 2002 and 2011. The subjects comprised patients with suspected autoinflammatory disease (90%) and a family history of CAPS, including family members of individuals in whom the V198M was identified (10%). Informed consent was provided by all subjects, and the ethical approval for the study was obtained from Royal Free Hospital and University College Medical School Research Ethics Committee for this retrospective study (REC reference number 06/Q0501/42)

Methods

Genetic analysis

DNA was extracted as previously described [19]. Exon 3 of *NLRP3/CIAS1* [NCBI RefSeqGene (LRG_197)] was

amplified in three fragments with the following primers: nucleotides: g.12654 to g.13428 with forward: 5'-GTTACCACTCGCTTCCGATG-3' and reverse: 5'-CCTCGTTCTCCTGAATCAGAC-3'; nucleotides: g.13397 to g.13972 with forward: 5'-CATGTGGA-GATCCTGGGTTT-3' and reverse: GGCCAAAGAG-GAAACGTACA-3' nucleotides: g.13955 to g.14523 with forward: 5'-ACTACCTGCTGGAAGAGGAA-3' and reverse: 5'-GCTGTGGCAACAGTATTTGGA-3'.

Negative and positive controls were included in each run. PCR was validated with gel electrophoresis, and PCR products were purified with a QIAquick PCR purification kit (Qiagen, Velno, The Netherlands) according to the manufacturer's protocol. Sequencing reaction was performed with Big Dye Terminator v. 3.1 Ready Reaction Cycle Sequencing kit (Applied Biosystems, Warrington, UK). The electrophoretic profiles of *NLRP3* sequences were analyzed on the ABI 3130xl Genetic Analyser by using Sequencing Analysis Software version 5.4.

Subjects who displayed features that may be seen in more than one of the currently described autoinflammatory syndromes underwent additional mutation screening of the following genes: *MEFV* (the gene associated with familial Mediterranean fever (FMF)) exons 2 and 10; *TNFRSF1A* (the gene associated with TNF receptor-associated periodic syndrome (TRAPS)) exons 2 to 7 including introns 2, 4, and 6; and *MVK* (the gene associated with mevalonate kinase deficiency (MKD), also known as hyper-IgD and periodic fever syndrome (HIDS)) exons 9 and 11.

Serial measurements of the acute-phase proteins

Serial measurements of the acute-phase proteins SAA and CRP were monitored monthly in symptomatic individuals. SAA was measured in serum with latex nephelometry (BNII autoanalyzer; Dade Behring, Marburg, Germany) [20]. The lower limit of detection was 0.7 mg/L, with an interassay coefficient of variation (CV) of 2.6% at 15 mg/L and 3.7% at 80 mg/L. CRP was measured in serum by using a high-sensitivity automated microparticle-enhanced latex turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics GmbH) [21,22]. The lower limit of detection was 0.2 mg/L, with an interassay CV of 4.2% at 4 mg/L and 6.3% at 1 mg/L.

Results

Genetic analysis

Pathogenic *NLRP3* variants were identified in 78 (9%) of the 830 screened subjects; most frequent was R260W, found in 23 (29%) cases, and V198M, identified in 19 (24%) individuals. We have not identified a second *NLRP3* variant, including the low-penetrance polymorphisms in the 19 subjects with V198M, but three had an amino acid variation in another fever gene: one was a compound heterozygote for *MVK* H44fs/V377I;

one was heterozygous for a novel variant in *TNFRSF1A* Y38S, and one was heterozygous for *MEFV* E148Q. The low-penetrance variants Q703K and R488K were found in 59 (7.1%) and four (0.5%) of the 830 screened cases, respectively.

Phenotypes associated with V198M

Clinical features associated with *NLRP3* V198M and response to treatment are summarized in Table 1.

Patients with CAPS phenotype

The V198M variant was identified in a Caucasian family with Muckle-Wells syndrome but with features overlapping both with FCAS and CINCA/NOMID (Family 1). The proband (subject 1) presented neonatally with a widespread urticarial rash affecting the entire body, particularly the trunk and distal limbs. The rash occurred on a daily basis and worsened with stress or after exposure to damp or cold. Other symptoms included swollen joints and severe ankle pain, generalized arthralgia, and hearing impairment, which was first noticed at age 5 years. Because of progressive hearing loss, hearing aids were required from the age of 27. Two of the proband's

children (subjects 2 and 3) have the same syndrome, and both developed sensory neural deafness in late childhood. All three subjects displayed mildly dysmorphic features characteristic of CINCA/NOMID, including short stature, frontal bossing of the skull, and flattening of the nasal bridge. The one unaffected child does not carry the V198M variant (Figure 1).


V198M was associated with FCAS in a Caucasian subject with no family history of CAPS (Figure 1), who developed a very diffuse urticarial rash in late childhood (subject 4, family 2). The rash was clearly precipitated by exposure to cold or damp environment and was associated with severe limb aching and swelling of the hands, face, legs, and feet (Figure 2). No ocular inflammation, hearing loss, or headaches were noted.

A diagnosis of MWS was made in a child of Northern European ancestry in association with V198M (subject 5), who presented at age 2 years with recurrent fever attacks lasting 2 to 14 days accompanied by arthralgia, myalgia, a diffuse urticarial rash, and headaches. The hearing was unaffected, and the febrile attacks were not precipitated by exposure to cold or damp environment.

Table 1 Phenotypes associated with *NLRP3* V198M variant and response to treatment

Kindred/subjects	Syndrome	Age at presentation (years)	Median SAA Pre/post treatment	Median CRP Pre/post treatment	Treatment	Mutations in other genes: <i>MEFV</i> , <i>TNFRSF1A</i> , and <i>MVK</i>
Family 1/Subject 1	CAPS (MWS/FCAS/CINCA)	Neonatal	193/3	42/1	Anakinra CR	None
Family 1/Subject 2	CAPS (MWS/FCAS/CINCA)	Neonatal	121/2	56.5/1	Anakinra CR	None
Family 1/Subject 3	CAPS (MWS/FCAS/CINCA)	Neonatal	133/3	42/1	Anakinra CR	None
Family 1/Subjects 13 and 14	Asymptomatic carriers	-	8	4	ND	ND
Family 2/Subject 4	CAPS (FCAS-type features)	11	ND / 3	ND / 1	Canakinumab CR	None
Family 2/Subjects 15 and 16	Asymptomatic carriers	-	3	1	ND	ND
None/Subject 5	CAPS (MWS-type features)	3	52/ND	ND	ND	None
Family 3/Subject 6	Schnitzler syndrome	57	299/6	156/1	Anakinra CR	None
Family 3/Subjects 17 and 18	Asymptomatic carriers	-	2	2	ND	ND
None/Subject 7	Positive rheumatoid factor polyarthritis	16	174 Lost to F/U	20 Lost to F/U	Anti-TNF therapy CR	None
None/Subject 8	Inflammatory syndrome	9	88/ND	16/ND	ND	None
None/Subject 9	Inflammatory syndrome	6 months	ND	133/ND	ND	None
Family 4/Subject 10	Undiagnosed chronic inflammatory syndrome	7	91.5/NR to treatment	54/NR to treatment	Anakinra NR	<i>MEFV</i> E148Q
Family 4/Subject 19	Asymptomatic carrier	-	3	2	ND	ND
None/Subject 11	MKD	Before 10	70/2	21/11	Anakinra PR	<i>MVK</i> H44fs/V377I
None/Subject 12	TRAPS complicated by AA amyloidosis	3	236.5/4	53.5/4	Anakinra CR	<i>TNFRSF1A</i> Y38S

CR, complete response; ND, not done; NR, no response; PR, partial response.



Patient with Schnitzler syndrome

V198M was an unexpected finding in a Caucasian patient who developed persistent flulike symptoms in the sixth decade accompanied by urticarial rash, general malaise, headaches, myalgia, night sweats, and mouth ulcers (subject 6, family 3). These inflammatory symptoms were clearly precipitated by stress. Initially thought to have vasculitis, for which extensive investigations had been made, the patient had failed to respond to broad-spectrum immunosuppression, rituximab, or anti-tumor necrosis factor (TNF) therapy. After the detection of a low-grade IgM κ -secreting lymphoplasmacytic lymphoma, the diagnosis of Schnitzler syndrome was made (Figure 1).

Patients with other autoinflammatory phenotypes

V198M variant was found in a subject of Arabic ancestry, first seen at the age of 16 years with an aggressive positive rheumatoid factor polyarthritis (subject 7).. There was a partial response to methotrexate but the patient then developed 2.6 g/day proteinuria. A renal biopsy was apparently normal, showing no evidence of AA amyloid deposits, and anti-TNF therapy resulted in a good response with resolution of proteinuria.

V198M was identified in two children; one of Caucasian ancestry who had 2- to 3-day attacks of fever

accompanied by cervical lymphadenopathy, myalgia, headache, and abdominal pain; the other was Asian and presented with fever and rash at the age of 6 months (subjects 8 and 9).

Patients with compound genetic variants

We identified three subjects who, in addition to V198M, also had an amino acid variation in another fever syndrome.

First was a Caucasian subject with an uncharacterized long-standing systemic inflammatory disorder with prominent bony abnormalities (subject 10, family 4), first seen at the age of 7 years with lower-leg and knee pain and was initially thought to have systemic onset juvenile idiopathic arthritis (SoJIA). An osteotomy of the left femur was performed in the early teens, followed by extensive reactive bone growth with a honeycomb appearance on radiograph above the resection site. After developing similar hyperostotic appearances at the distal end of the right femur SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome was considered, although none of the other features was present. The patient never experienced episodes of fever or serositis, and the single episode of rash was a drug reaction after antibiotics during the late teens. Screening of the genes associated with other hereditary autoinflammatory



Figure 2 Diffuse rash precipitated by cold or damp environment in subject 4 diagnosed with familial cold autoinflammatory syndrome (FCAS).

syndromes, FMF, TRAPS, and MKD, revealed a heterozygous status for the *MEFV* E148Q polymorphism.

The other two subjects were first seen before the age of 10 years (subject 11) and in the eighth decade with AA amyloidosis and a life-long history of fevers and episodic abdominal pain (subject 12). The first case

was diagnosed with two *MVK* variants, H44fs and V377I, and met the clinical criteria for diagnosis of MKD. The second patient was found to be heterozygous for a novel variant in *TNFRSF1A* Y38S, and the inflammatory syndrome was thought to be fully consistent with TRAPS.

Asymptomatic carriers of V198M

V198M appeared to have no clinical consequences in seven asymptomatic carriers detected as part of family screening: (subjects 13 through 19). CRP and SAA measurements in these individuals did not reveal any evidence of subclinical inflammatory disease.

Laboratory and clinical response to IL-1 therapy

SAA and CRP were measured in 10 of the 12 affected individuals before treatment was commenced and are outlined in Table 1. Median values were SAA 141.5 mg/L (range, 52 to 299 mg/L) and CRP 54, mg/L (range, 20 to 156 mg/L). Eight patients were treated with anti-IL-1 therapy: anakinra in seven including three non-CAPS patients diagnosed with Schnitzler syndrome, TRAPS, and MKD, respectively (at a dose of 100 mg daily for adults and 1 mg/kg for children), and canakinumab in one (at a dose of 150 mg), and all but one (subject 10) responded completely with rapid resolution of symptoms and normalization of SAA concentration to healthy values of <4 mg/L. Subject 7 had been treated with anti-TNF therapy and showed significant improvement.

Discussion

Cryopyrin-associated periodic syndrome is an inherited autoinflammatory disorder characterized by episodes of fever, urticarial rash, arthralgia, myalgia, eye inflammation, and, in its more severe forms, bony abnormalities and CNS inflammation.

CAPS is caused by autosomal-dominant gain-of-function mutations of the *NLRP3* gene (NCBI RefSeqGene (LRG_197)) located on chromosome 1q44, resulting in increased production of IL-1 β [23-25]. Despite the dramatic advances in unraveling the pathophysiology of CAPS, including identification of the gene [26-28], the *NLRP3* inflammasome [1], and the introduction of highly effective treatment in the form of IL-1-blocking drugs [29-31], our understanding of this disease is incomplete. The exact mechanisms by which *NLRP3* mutations lead to activation of the inflammasome and overproduction of IL-1 β remain unclear. At present, an apparent lack of correlation exists between genotype and phenotype in general and even within a family, and the relation between mutation and clinical phenotype can differ markedly between individuals [10]. Both *NLRP3* R260W and V198M have been reported in patients with phenotypes overlapping FCAS and MWS [3,27,32], and D303N has been associated with MWS and CINCA/NOMID [33]. Forty percent of children with CINCA/NOMID are reported to be "mutation negative" by conventional genomic sequencing from whole blood. Interestingly, recent publications described a high incidence of somatic mosaicism among mutation-negative CINCA patients. Tanaka *et al.* [34]

identified somatic mutations in 18 (69.2%) of 26 patients, with the level of mosaicism ranging from 4.2% to 35.8% by subcloning of the PCR products followed by capillary DNA sequencing of more than 100 subclones for each patient [34]. The latest advances in molecular biology allow rapid and accurate diagnoses of mosaic patients by massive parallel DNA sequencing, which can detect base substitutions at an allele frequency as low as 1% with 99.9% confidence [35].

NLRP3 V198M has been previously reported as a low-penetrance mutation in CAPS, a finding in healthy populations and a factor that may exacerbate or modify the clinical phenotype of autoinflammatory disorders other than CAPS. An example of this is the case described by Singh-Grewal *et al.* [16] of a patient with *NLRP3* V198M first seen at the age of 6 years with progressive sensorineural deafness followed within a couple of years by recurrent fever, abdominal pain, and arthritis. Screening for *MEFV* revealed she was a compound heterozygote for V726A, I692del, and E148Q, and was diagnosed with FMF. She was noncompliant to treatment with colchicine and died of renal AA amyloidosis at the age of 13 years. Another example, in this case of overlapping TRAPS/CAPS phenotype, was described in 2006 of a 36-year-old French woman and her mother, both with *NLRP3* V198M and *TNFRSF1A* R92Q. Their symptoms, including fever, urticarial rash, arthralgia, myalgia, aphthosis, edema, fatigue, and conjunctivitis, were precipitated by exposure to heat and water. The proband's daughter, who only had *TNFRSF1A* R92Q, had a much milder disease, and the proband's grandmother and stepbrother, who carried *TNFRSF1A* R92Q and *NLRP3* V198M, respectively, were completely asymptomatic [17].

Variants in other hereditary periodic fever syndromes such as in FMF E148Q and in TRAPS R92Q have also been described with a number of inflammatory disorders [36-39]. These low-penetrance mutations/polymorphisms have a relatively high prevalence in certain populations; R92Q is present in 2% of North Americans and Irish [36,37,40], and E148Q, in 20% of Asians [41]. Although they may have clinically significant proinflammatory effects in some cases, their implication in the disease cause remains dubious [36,37,40,42].

The finding of V198M in a patient with Schnitzler syndrome is particularly intriguing. Schnitzler syndrome is an adult-onset, apparently acquired disease, which clinically closely resembles CAPS. Fewer than 100 cases have been reported since it was first described in 1972 [43,44]. The main clinical features include fever, an urticarial rash, and muscle, bone, and/or joint pain. Other manifestations include lymphadenopathy (45%), hepatosplenomegaly (12%), and deafness (1%) [43]. A monoclonal IgM component is the biologic hallmark of the disease and is

thought to be central to its pathogenesis, although whether and how this is linked to increased secretion of IL-1 has not been established. Treatment was very unsuccessful until the introduction of anti IL-1 therapies, which result in complete disease remission and support the central role of IL-1 in the disease process [43,44]. A recent report describes the *NLRP3* V198M variant in a patient with Schnitzler syndrome [18]. Our finding of a second case supports the suggestion that a molecular link may exist between the *NLRP3* inflammasome and the mechanism by which the IgM paraprotein induces inflammation.

This is the largest reported cohort of individuals with V198M assessed in a single center. Our findings that V198M was associated with a variety of CAPS and other autoinflammatory phenotypes in 12 cases and was identified in seven asymptomatic individuals emphasizes the complexity of the genetics of these syndromes. In our center, the allele frequency of V198M among patients with clinical evidence of fever syndrome, excluding the family screening, was 0.8%, twice that reported in European healthy controls [11]. The valine amino acid at position 198 is not conserved in evolution, suggesting that it does not have key role in the function of cryopyrin. The different phenotypes observed in association with V198M further suggest that other, currently unknown, genetic and environmental factors contribute to its involvement in autoinflammatory disease. It is possible that variants of other components of the *NLRP3* inflammasome complex could play a role in disease pathogenesis, although this has not yet been systematically explored on a large scale.

Conclusions

The *NLRP3* V198M variant shows variable expressivity and reduced penetrance. It may be associated with classic inherited or apparently sporadic CAPS, and with atypical autoinflammatory disease of varying severity, intriguingly including Schnitzler syndrome. The factors that influence the pathogenic consequences of this variant remain unknown. However, the remarkable response to IL-1 blockade in all but one individual in our series confirms that the clinical features are indeed mediated by IL-1.

Abbreviations

CAPS: cryopyrin-associated periodic syndrome; CINCA: chronic infantile neurologic cutaneous articular syndrome; CRP: C-reactive protein; FCAS: familial cold autoinflammatory syndrome; FMF: familial Mediterranean fever; HIDS: hyper-IgD and periodic fever syndrome; MKD: mevalonate kinase deficiency; MWS: Muckle-Wells syndrome; NOMID: neonatal-onset multisystem inflammatory disease; SAA: serum amyloid A protein; SAPHO: synovitis; acne: pustulosis; hyperostosis; and osteitis; SoJIA: systemic-onset juvenile idiopathic arthritis; TRAPS: TNF-receptor-associated periodic syndrome.

Authors' contributions

The manuscript has been read and approved by all of the authors. The contribution of each author listed in this publication was as follows: study conception and design, and final approval of the manuscript was performed by HJL and PNH; drafting of the manuscript and data analysis was performed by DMR and HJL; genetic screening was performed by DMR, HT, TR, and AB; patient clinical assessment was performed by: TL, NMS, JDG, PW, BM, HJL, and PNH.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

We thank all the physicians who were involved in the clinical care of the patients reported in this study.

Author details

¹National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine Royal Free Campus, UCL Medical School, Rowland Hill Street, London NW3 2PF, UK. ²Division of Infection & Immunity, UCL, Rayne Building, 5 University Street, London WC1E 6JF, UK. ³Department of Pediatrics and Developmental Disorders, Children's Teaching Hospital, Waszyngtona Street 17, Bialystok 15-224, Poland.

Received: 20 July 2012 Revised: 6 December 2012

Accepted: 12 February 2013 Published: 19 February 2013

References

1. Martinon F, Burns K, Tschopp J: **The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1 β** . *Mol Cell* 2002, **10**:417-426.
2. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, Moore TL, Schikler K, Hoffman H, Lovell DJ, Lipnick R, Barron K, O'Shea JJ, Kastner DL, Goldbach-Mansky R: **De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases**. *Arthritis Rheum* 2002, **46**:3340-3348.
3. Dodé C, Le Du N, Cuisset L, Letourneur F, Berthelot JM, Vaudour G, Meyrier A, Watts RA, Scott DGI, Nicholls A, Granel B, Frances C, Garcier F, Ederly P, Boulinguez S, Domergues JP, Delpech M, Grateau J: **New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes**. *Am J Hum Genet* 2002, **70**:1498-1506.
4. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner J: **Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome**. *Nat Genet* 2001, **29**:301-305.
5. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, Teillac-Hamel D, Fischer A, de Saint Basile G: **Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes**. *Am J Hum Genet* 2002, **71**:198-203.
6. Kile RL, Rusk J: **A case of cold urticaria with an unusual family history**. *JAMA* 1940, **114**:1067-1068.
7. Doeglas HMG, Bleumink J: **Familial cold urticaria. Clinical findings**. *Arch Dermatol* 1974, **110**:382-388.
8. Commerford PJ, Meyers J: **Arthropathy associated with familial cold urticaria**. *S Afr Med J* 1977, **51**:105-108.
9. Lieberman A, Grossman ME, Silvers J: **Muckle-Wells syndrome: case report and review of cutaneous pathology**. *J Am Acad Dermatol* 1998, **39**:290-291.
10. Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott J: **Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis**. *Arthritis Rheum* 2002, **46**:2445-2452.

11. Aksentijevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner J: **The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.** *Arthritis Rheum* 2007, **56**:1273-1285.
12. Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins J: **Natural history and outcome in systemic AA amyloidosis.** *N Engl J Med* 2007, **356**:2361-2371.
13. Toutou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C, Shoham N, Aganna E, Hugot JP, Wise C, Waterham H, Pugnere D, Demaille J, Sarrauste de Menthieri C: **Infervers: an evolving mutation database for auto-inflammatory syndromes.** *Hum Mutat* 2004, **24**:194-198.
14. Verma D, Sarndahl E, Andersson H, Eriksson P, Fredrikson M, Jonsson JJ, Lerm M, Soderkvist J: **The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1beta and IL-18 production.** *PLoS One* 2012, **7**:e34977.
15. Porksen G, Lohse P, Rosen-Wolff A, Heyden S, Forster T, Wendisch J, Heubner G, Bernuth H, Sallmann S, Gahr M, Roesler J: **Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients: expanding phenotype of CIAS1 related autoinflammatory syndrome.** *Eur J Haematol* 2004, **73**:123-127.
16. Singh-Grewal D, Chaitow J, Aksentijevich I, Christodoulou J: **Coexistent MEV and CIAS1 mutations manifesting as familial Mediterranean fever plus deafness.** *Ann Rheum Dis* 2007, **66**:1541.
17. Toutou I, Perez C, Dumont B, Federici L, Jorgensen J: **Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations.** *Ann Rheum Dis* 2006, **65**:1530-1531.
18. Loock J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross J: **Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome.** *J Allergy Clin Immunol* 2010, **125**:500-502.
19. Talmud P, Tybjaerg-Hansen A, Bhatnagar D, Mbewu A, Miller JP, Durrington P, Humphries J: **Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia.** *Atherosclerosis* 1991, **89**:137-141.
20. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Rifai J: **Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum.** *Ann Clin Biochem* 1998, **35**:745-753.
21. Wilkins J, Gallimore JR, Moore EG, Pepys J: **Rapid automated high sensitivity enzyme immunoassay of C-reactive protein.** *Clin Chem* 1998, **44**:1358-1361.
22. Eda S, Kaufmann J, Molwitz M, Vorberg J: **A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease.** *Scand J Clin Lab Invest* 1999, **230**:32-35.
23. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J: **NALP3 forms an IL-1 β -processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.** *Immunity* 2004, **20**:319-325.
24. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung J: **In vivo regulation of interleukin 1 β in patients with cryopyrin-associated periodic syndromes.** *J Exp Med* 2009, **206**:1029-1036.
25. Glaser RL, Goldbach-Mansky R: **The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies.** *Curr Allergy Asthma Rep* 2008, **8**:288-298.
26. Hoffman HM, Wright FA, Broide DH, Wanderer AA, Kolodner J: **Identification of a locus on chromosome 1q44 for familial cold urticaria.** *Am J Hum Genet* 2000, **66**:1693-1698.
27. McDermott MF, Aganna E, Hitman GA, Ogunkolade BW, Booth DR, Hawkins J: **An autosomal dominant periodic fever associated with AA amyloidosis in a north Indian family maps to distal chromosome 1q.** *Arthritis Rheum* 2000, **43**:2034-2040.
28. Cuisset L, Drenth JPH, Berthelot JM, Meyrier A, Vaudour G, Watts RA, Scott DGI, Nicholls A, Pavsek S, Vasseur C, Beckmann JS, Delpech M, Grateau J: **Genetic linkage of the Muckle-Wells syndrome to chromosome 1q44.** *Am J Hum Genet* 1999, **65**:1054-1059.
29. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins J: **A randomized trial of canakinumab in cryopyrin-associated periodic syndrome.** *N Engl J Med* 2009.
30. Hawkins PN, Lachmann HJ, McDermott J: **Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.** *N Engl J Med* 2003, **348**:2583-2584.
31. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis J: **Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.** *Arthritis Rheum* 2008, **58**:2443-2452.
32. Hawkins PN, Lachmann HJ, Aganna E, McDermott J: **Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.** *Arthritis Rheum* 2004, **50**:607-612.
33. Granel B, Philip N, Serratrice J, Ene N, Grateau G, Dode C, Cuisset L, Disdir P, Berbis P, Delpech M, Weiller J: **CIAS1 mutation in a patient with overlap between Muckle-Wells and chronic infantile neurological cutaneous and articular syndromes.** *Dermatology* 2003, **206**:257-259.
34. Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O, Nishikomori R, Morimoto T, Kambe N, Goldbach-Mansky R, Aksentijevich I, de Saint Basile G, Neven B, van Gijn M, Frenkel J, Arostegui JI, Yague J, Merino R, Ibanez M, Pontillo A, Takada H, Imagawa T, Kawai T, Yasumi T, Nakahata T, Heike J: **High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study.** *Arthritis Rheum* 2011, **63**:3625-3632.
35. Izawa K, Hijikata A, Tanaka N, Kawai T, Saito MK, Goldbach-Mansky R, Aksentijevich I, Yasumi T, Nakahata T, Heike T, Nishikomori R, Ohara J: **Detection of base substitution-type somatic mosaicism of the NLRP3 gene with >99.9% statistical confidence by massively parallel sequencing.** *DNA Res* 2012, **19**:143-152.
36. Ravet N, Rouaghe S, Dode C, Bienvenu J, Stirnemann J, Levy P, Delpech M, Grateau J: **Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene.** *Ann Rheum Dis* 2006, **65**:1158-1162.
37. D'Ossualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, Pontillo A, Corona F, Barcellona R, Di Duca M, Santamaria G, Traverso F, Picco P, Baldi M, Plebani A, Ravazzolo R, Ceccherini I, Martini A, Gattorno J: **Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications.** *Arthritis Rheum* 2006, **54**:998-1008.
38. Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner J: **The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations.** *Curr Opin Rheumatol* 2003, **15**:61-69.
39. Lamprecht P, Moosig F, Adam-Klages S, Mrowietz U, Csernok E, Kirrstetter M, Ahmadi-Simab K, Schroder JO, Gross J: **Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS).** *Ann Rheum Dis* 2004, **63**:1518-1520.
40. Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, Goldbach-Mansky R, Dean J, Athreya B, Reginato AJ, Henrickson M, Pons-Estel B, O'Shea JJ, Kastner J: **The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.** *Am J Hum Genet* 2001, **69**:301-314.
41. Booth DR, Lachmann HJ, Gillmore JD, Booth SE, Hawkins J: **Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148.** *QJ Med* 2001, **94**:527-531.
42. Toutou J: **The spectrum of familial mediterranean fever (FMF) mutations.** *Eur J Hum Genet* 2001, **9**:473-483.
43. de Koning HD, Bodar EJ, van der Meer JW, Simon A: **Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment.** *Semin Arthritis Rheum* 2007, **37**:137-148.
44. Lipsker J: **The Schnitzler syndrome.** *Orphanet J Rare Dis* 2010, **5**:38.

doi:10.1186/ar4171

Cite this article as: Rowczenio *et al.*: Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. *Arthritis Research & Therapy* 2013 **15**:R30.